ArticleBMC pediatrics2025
Hearing assesment in children after intrauterine exposure to platinum-based treatment of pregnant cancer patients: A study from the International Network on Cancer, Infertility and Pregnancy.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundLiterature on the effects of prenatal exposure to platinum-based chemotherapy on the auditory capacity of the offspring is scarce. The current study aims to describe the occurrence of hearing impairment in a well-documented series of children who underwent audiological testing.
methodsAn international, descriptive multicentre study using oncological, obstetrical, and neonatal data registered by the International Network of Cancer Infertility and Pregnancy database, was performed. The offspring (aged ≥ 4 years) underwent pure tone audiometry. Audiological outcomes were registered after expert review, using international standardized audiological grading as developed for platinum exposed childhood cancer patients: the Muenster criteria and the International Society for Paediatric Oncology classification. Platinum-induced hearing loss was defined as bilateral hearing loss, starting at 8 kHz and without middle ear problems confirmed by tympanometry or otoscopy.
findingsTwenty-five children were included of which 17 children (68%) had been exposed to cisplatin and 8 (32%) to carboplatin, none to both. Median gestational age at start maternal treatment was 22 weeks (range, 14–31). Median gestational age at delivery was 35 weeks (range, 31–39), and median birth weight was 2345 g (range, 1526–3360). Neonatal hearing screening, performed in 10 children (40%), showed no hearing loss. At a median age of 6.0 years (range, 4.0–28.0), 6 children (24%) revealed bilateral hearing loss, using cut-off values of Muenster grade ≥ 2b and SIOP grade ≥ 2.
interpretationAntenatal exposure to platinum-based chemotherapy is associated with hearing loss in a subset of the offspring. Prospective longitudinal standardized surveillance of auditory function is advised, starting after birth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.